UBS Maintains Buy on Bio-Rad Laboratories, Lowers Price Target to $310
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
UBS analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:BIO) with a Buy and lowers the price target from $355 to $310.
UBS analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:BIO) with a Buy and lowers the price target from $355 to $310.